Clinigen Group PLC (CLIN) Earns “Buy” Rating from Numis Securities Ltd
Numis Securities Ltd reiterated their buy rating on shares of Clinigen Group PLC (LON:CLIN) in a research report released on Wednesday. They currently have a GBX 933 ($12.18) target price on the stock.
Several other analysts have also recently issued reports on CLIN. Peel Hunt restated a buy rating and issued a GBX 1,000 ($13.05) target price on shares of Clinigen Group PLC in a report on Wednesday, September 28th. N+1 Singer restated a buy rating and issued a GBX 800 ($10.44) target price on shares of Clinigen Group PLC in a report on Wednesday, September 28th. Finally, Stifel Nicolaus restated a buy rating and issued a GBX 800 ($10.44) target price on shares of Clinigen Group PLC in a report on Wednesday, July 20th. Five research analysts have rated the stock with a buy rating, Clinigen Group PLC currently has a consensus rating of Buy and a consensus price target of GBX 856.60 ($11.18).
Shares of Clinigen Group PLC (LON:CLIN) opened at 779.14 on Wednesday. Clinigen Group PLC has a 12-month low of GBX 492.75 and a 12-month high of GBX 793.50. The company’s market capitalization is GBX 892.89 million. The company has a 50 day moving average price of GBX 658.86 and a 200 day moving average price of GBX 600.08.
The firm also recently declared a dividend, which will be paid on Friday, November 25th. Stockholders of record on Thursday, November 3rd will be issued a dividend of GBX 2.70 ($0.04) per share. The ex-dividend date is Thursday, November 3rd. This is a boost from Clinigen Group PLC’s previous dividend of $1.30. This represents a dividend yield of 0.38%.
About Clinigen Group PLC
Clinigen Group plc is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates through four segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA) and Clinigen Specialty Pharmaceuticals (SP).
Receive News & Ratings for Clinigen Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.